Purpose Germline mutations in BRCA1 and BRCA2 confer a significant increase in risk for cancer, and determining pathogenicity of a BRCA variant can guide the clinical management of the disease. About 1/3 of BRCA1 variants reported in the public databases have uncertain clinical significance due to lack of conclusive evidence. This study aims to characterize a novel BRCA1 deletion affecting the + 4 splice donor site identified in an individual with early-onset breast cancer. Methods The effect of BRCA1 c.5332+4delA variant on RNA splicing was evaluated by amplifying regions of BRCA1 from cDNA derived from the patient. The proportion of abnormal transcript in the total transcripts was quantified. Loss of heterozygosity (LOH) in tumor tissue was investigated using Sanger sequencing and fragment analysis. Results BRCA1 c.5332+4delA caused skipping of exon 21 in patient-derived samples. Semi-quantitative analysis indicated that this aberrant RT-PCR product accounts for about 40% of the total transcript levels. Loss of heterozygosity (LOH) was observed in patient's tumor tissue. Conclusions Our results indicate that the BRCA1 c.5332+4delA variant contributes to cancer predisposition through disruption of normal mRNA splicing. We classify this variant as likely pathogenic.
Introduction
BRCA1 is a major component of the homologous repair (HR) pathway and is responsible for the regulation of DNA double-strand break repair [1, 2] . The BRCA1 protein comprises a highly conserved RING finger domain at the N terminus and two repeats of the BRCA1 C-terminal (BRCT) domain at the C terminus [3] . The BRCT repeats play essential roles in tumor suppression, DNA damage repair, and transcriptional regulation [4] . Deletion of the last 11 amino acids of the second BRCA1 BRCT domain, which disrupts BRCA1 protein folding and restricts its nuclear localization [4, 5] , is associated with early-onset breast cancer [6] .
Germline mutations in BRCA1 significantly increase lifetime risk of breast and ovarian cancer [7] . By the age of 70 years, the absolute risk of cancer for female BRCA1 mutation carriers is reported to be approximately 60-71% for breast cancer and 39-59% for ovarian cancer [8] [9] [10] [11] . However, a substantial proportion of these alterations are classified as variants of uncertain significance (VUS). ClinVar, the freely accessible public archive of genetic variants, has 5622 BRCA1 entries, of which 1863 are VUSs (33%) [12, 13] . The ambiguity of VUS is problematic and complicates cancer risk assessment for patients and their family members who carry these variants of uncertain significance, since they cannot take advantage of cancer prevention measures or therapeutic treatment such as PARP inhibitors.
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intronic variants beyond the ± 1-2 bps can be challenging because it is not known whether these subtle changes sufficiently and consistently affect normal splicing to predispose to cancer development. Intronic variants could lead to either complete skipping of one or more exons, intronic retention, activation of neighboring cryptic splice sites, or introduction of a new splice site within an exon or intron [14] . In some cases, exon skipping causes a frameshift and generates premature termination codons. The aberrant mRNA is degraded by nonsense-mediated RNA decay, and the abnormal transcript is hard to detect. In other cases, the aberrant splicing products are relatively stable, and an abnormal PCR band is observed after RT-PCR [15] . Alternatively spliced isoforms of BRCA1 occur naturally in non-malignant tissues and several isoforms have been reported to consistently occur in control samples [16, 17] . Comprehensive studies on BRCA1 splicing events in blood-related and healthy breast tissue samples by the ENIGMA consortium, an international network of collaborators focused on determining and disseminating the clinical significance of variants in BRCA1, BRCA2, and other breast cancer-associated genes [18] , suggest that non-mutually exclusive splicing events are randomly combined to produce several different naturally occurring BRCA1 isoforms [16] , further complicating the interpretation of a potential splicing variant. To date, over 160 pathogenic or likely pathogenic BRCA1 splice site variants are reported in ClinVar (https://www.ncbi.nlm.nih.gov/ clinvar).
Several studies have reported mutations occurring at the beginning of the intron 21 of BRCA1 (NM_007294.3, lack of exon 4), including a pathogenic variant c.5332+1G>A that causes aberrant splicing and results in the loss of the entire exon 21 [19] [20] [21] [22] . The c.5332+1delG mutation was identified in a Chinese woman with early-onset breast cancer [23] and the mutation c.5332+1G>C was reported in a woman with family history of breast cancer [24] . BRCA1 c.5332G>A and c.5332G>T, which occur at the last nucleotide of exon 21, were shown to similarly affect function in experimental studies and classified as pathogenic variants [25] . In this study, we characterized a VUS affecting the same donor splice site, c.5332+4delA, which was identified through clinical testing. This variant leads to exclusion of the entire exon 21 and presumably causes premature truncation of the protein. Loss of heterozygosity (LOH) analysis in the patient tumor sample demonstrated a strong tendency to induce LOH of the wildtype allele in the tumor. Based on our data, we classify this variant as likely pathogenic.
Materials and methods

The Subject
The patient described here is a 33-year-old female who was diagnosed with breast cancer at age 33. Her maternal uncle and grandfather were diagnosed with prostate cancer at 55 and 75 years of age, respectively. Her maternal grandmother was diagnosed with T cell lymphoma in her 80s. The proband's paternal grandfather was affected with pancreatic cancer at 83. Her paternal grandmother was diagnosed with endometrial cancer at age 65 and breast cancer at 74 (Fig. 1) . The BRCA1 c.5332+4delA variant, reported as VUS, was identified through clinical breast cancer panel testing with seven genes evaluated (ATM, BRCA1, BRCA2, CHEK2, PALB2, PTEN, and TP53) in a commercial laboratory. No other reportable variants were identified by sequencing or deletion/duplication in the remaining 6 genes analyzed. Given the uncertain clinical significance of this variant, the patient provided written informed consent for genetic testing as part of a study approved by the Institutional.
Review Board of MSKCC (protocol #96-051 "Clinical Significance of Germline BRCA Mutations"). Peripheral blood samples were collected using the EDTA Blood tube and PAXgene Blood RNA tube (Qiagen, Valencia, CA) and submitted to the Diagnostics Molecular Genetics Laboratory at MSKCC for further analysis. Control RNAs were extracted from unrelated individuals seen at MSKCC who do not carry the BRCA1 variant. Primers were designed using the Primer 3 software (http://bioinfo.ut.ee/primer3-0.4.0/). In silico prediction of its effects on splicing was performed using Alamut (Interactive Biosoftware), which includes SSF, MaxEnt, NNSPLICE, GeneSplicer, and HSF tools.
cDNA analysis
Total RNA was extracted using the PAXgene BloodRNA Kit (PreAnalytiX, Qiagen, Valencia, CA) and was subsequently used for cDNA synthesis (SuperScript III FirstStrand Synthesis SuperMix, Invitrogen Life Technologies, Carlsbad, CA). Control RNA was extracted from 12 individuals who did not carry the BRCA1 variant. DNase I was used to remove DNA during RNA extraction. Reverse transcription was conducted using SuperScript III FirstStrand Synthesis SuperMix (Invitrogen) in the presence of 2.3 µM Oligo(dT) 20 . PCR was performed using the JumpStart REDTaq Ready Mix (Sigma), with control cDNA or the patient's cDNA in the presence of M13-tagged forward and reverse primers (Forward, 5′-GTA AAA CGA CGG CCA GTA AAG AAA GAA AAA TGC TGA ATGA-3′; Reverse: 5′-CAG GAA ACA GCT ATG ACA CCA CAA TTG GGT GGA CA-3′). Every PCR reaction contained 12. 
Fragment analysis
RT-PCR were performed using primers with the same sequences and PCR conditions as mentioned above in the cDNA analysis, except that the reverse primer was labeled with 5′JOE fluorophore. The RT-PCR products were subjected to fragment analysis on 3730 Genetic Analyzer (Applied Biosystems, Foster City, CA) using the internal lane standard 600 (ILS 600) (Promega Corporation, Madison, WI) as a DNA ladder to assign correct sizes to DNA fragments. The proportions of different transcripts were calculated based on the peak heights of each fragment.
Loss of heterozygosity (LOH) analysis in tumor tissue
Loss of heterozygosity analysis was performed in breast cancer tissue samples from the patient. Sections of the paraffin-embedded breast carcinoma sample were stained by hematoxylin and eosin (H&E) using standard protocols. Tumor cells were collected and deparaffinized. DNA extraction was performed using the Qiagen DNeasy Tissue Kit (Cat# 69,504, Qiagen). Tumor DNA was amplified using PCR (Forward primer: 5′-CTT CTC TCC ATT CCC CTG TC-3′; Reverse primer: 5′-CAT CGT GGG ATC TTG CTT AT-3′)
The PCR products were run on QIAxcel (Qiagen, Valencia, CA) to confirm successful amplification. The PCR products were subjected to direct DNA sequence analysis and fragment analysis performed by a 3730 DNA Analyzer (Applied Biosystems, Foster City, CA).
Results
The BRCA1 c. 5332+4delA variant disrupts normal mRNA splicing
To evaluate the potential effects of the variant on splicing, we used Alamut software, which incorporates five tools to predict the potential effects of BRCA1 c.5332+4delA on normal mRNA splicing. Four out of five tools predicted that the variant significantly weakens the 5′ donor splice site by more than 20% (Fig. 2a, b) .
The effect of BRCA1 c. 5332+4delA variant on RNA splicing was subsequently evaluated by amplifying regions of BRCA1 from cDNA derived from the patient. PCR was designed to generate a fragment that spanned part of exon 19, the entire coding region of exons 20-22, and part of exon 23, which are likely affected by the variant. An additional band, which is absent in 12 controls, was identified in the patient (lane 14, Fig. 3a) . This band represents an aberrant RNA splicing product attributable to this variant. Further sequencing revealed that this variant leads to loss of the entire exon 21, which contains 55 nucleotides (Fig. 3b) . Semi-quantitative analysis from 5 patient replicates and 12 negative controls indicated that this aberrant RT-PCR product accounts for about 40% of the total transcript levels (Fig. 3c) . We also performed BRCA1 full gene sequencing on patient sample to identify potential SNPs that might be used to address whether the mutant allele completely disrupts normal splicing. Unfortunately, we did not find any SNPs in the exonic regions and were unable to perform SNP tagging to exclude the possibility that the mutant allele still produces full-length transcript.
Loss of heterozygosity (LOH) analysis in tumor tissue
To investigate whether the patient's tumor sample exhibits loss of the wild-type allele, DNA was extracted from the patient's tumor and amplified along with DNA from both the patient's normal tissue (peripheral blood) and a normal control sample that does not carry the BRCA1 variant. PCR fragments were sequenced (Fig. 4a) and analyzed using fragment analysis (Fig. 4b) . As expected, patient's normal tissue showed two alleles of approximately equal peak heights indicating heterozygous status (Fig. 4a, b) . In the tumor sample, the c.5332+4delA allele was the major allele, and the peak height of the wild-type c.5332+4A allele was significantly reduced compared with that in patient's normal samples (Fig. 4a, b) . Fragment analysis was used to quantify the percentage of LOH (Fig. 4b) . The patient DNA from normal blood comprises of both the wild-type and mutant alleles accounting for approximately 48.15 and 51.85% of the total transcript levels. In contrast, in the tumor sample, the wild-type allele significantly decreased to 1.5% and the c.5332+4delA mutant increased to 98.5%. LOH is defined as a signal reduction of 25% or more of one allele in the tumor sample, when compared with the normal sample, and was calculated as follows: [100% − percentage of wild-type allele in tumor tissue/percentage of wild-type allele in normal tissue] = [100% − 1.5%/48.15% = 97%]. The percentage of the wild-type allele in the above equation was calculated as an average of peak height × peak area of wild-type allele/ sum of peak heights × peak areas of wild-type and mutant alleles from at least six independent experiments. Our data showed 97% signal reduction of the wild-type allele in the tumor compared to control samples demonstrating the loss of wild-type BRCA1 allele in the tumor.
Discussion
This variant, BRCA1c.5332+4delA, affecting the donor splice site at the exon-intron 21 junction was identified in an individual with early-onset ER+/PR+/HER2− breast cancer with limited family history. The external commercial laboratory classified it as a VUS which was deposited into ClinVar. This rare variant is absent from the population databases and our cohort of more than 15,000 individuals undergoing germline testing. However, this variant was identified in 1/478 individuals with early-onset, high-risk breast cancer Fig. 2 In silico predictions of the BRCA1 c.5332+4delA variant. The Alamut software was used to evaluate the potential effects of the variant on splicing. Four out of five tools predicted that the variant weakens the 5′ donor splice site, causing an average 25% loss of function with estimates ranging from a loss of 7-40% [26] . Further studies demonstrated this variant segregates with breast and ovarian cancer in the family. Experimental studies showed exon skipping similar to our observations, and a functionally impaired protein [27] . BRCA1 mutation carriers are typically diagnosed with high grade, early-onset, triple-negative breast cancers (TNBC) [28, 29] and morphological features can be useful in interpreting variants [30] ; however, cases of early-onset breast cancer that are not TNBC have been reported. Interestingly, the splice site variant c.5332+1G>A, which affects the same donor site as c.5332+4delA, was observed de novo in an individual with bilateral early-onset breast cancer with a pathological profile similar to our case (ER+/PR+) [20] . Functional studies using patient-derived DNA showed c.5332+1G>A which resulted in full-length and exon 21-skipped RT-PCR products [19] , similar to c.5332+4delA, and was classified pathogenic by ENIGMA. It is worth mentioning neither parent of our proband carries the BRCA1 c.5332+4delA variant, which indicates it is likely a de novo mutation (paternity testing not performed). Alternatively spliced isoforms of BRCA1 have been identified in normal tissues, particularly isoforms skipping all or part of exon 11 [16, 17, 31] . The relative levels of these alternatively spliced isoforms appear to influence DNA synthesis and cancer cell proliferation. At least one of these isoforms appeared to regulate cell proliferation by altering subcellular localization. Naturally occurring isoforms missing exon 21 are uncommon; we detected less than 1% of alternatively spliced transcripts with exon 21 deleted in our control samples. Similarly, minimal levels of alternatively spliced transcripts with exon 21 deletion were seen in the control sample for the pathogenic c.5332+1G>A variant [19] although this was not quantified. The deletion of exon 21 would cause a frameshift that presumably creates a premature stop codon and leads to the loss of 90 amino acids within BRCA1 BRCT domain. We observed LOH of the variant allele in our patient's tumor sample, which would be expected for a pathogenic variant. While it is commonly observed in breast cancers, LOH is not currently included in the criteria for variant classification according to ACMG guidelines [32] .
This work highlights the lack of concordance sometimes seen between computational algorithms and experimental studies on analyzing splice variants, and the implications of in silico prediction in interpretation of intronic and synonymous variants. While five algorithms predict c.5332+4delA causes loss of function at the donor splice site 4 bp upstream, the predicted loss averages 25%, with the mutated sequence predicted to be significantly stronger than any cryptic donor sites in the vicinity. The functional evidence from our study suggests the effect is much more pronounced with a 60:40 ratio of full length: exon 21-skipped transcripts in our patient sample, similar to the results from c.5332+1G>A which is predicted to cause 100% loss of function at the canonical donor site [19] . Our observations are in line with the potential effects caused by the disruption of both the + 4 and + 5 positions of a consensus 5′ splice site sequence, which are predominantly AG [33, 34] . Several other BRCA1 variants affecting these sites have been reported pathogenic by multiple labs in the ClinVar database, including variants at c.4986+4A/+5G, c.5152+4A/+5G, c.5406+4A/+5G, and c.8754+4A/+5G, all of which alter the A or G nucleotides at the + 4 or + 5 sites, respectively. One limitation of this study is the absence of other SNVs in the entire BRCA1 coding region observed by BRCA1 full gene sequencing in our patient, precluding SNP tagging analysis to determine whether the mutant allele can generate normal transcripts.
Advances in NGS technology have facilitated the generation of large amounts of potentially actionable genomic data, but have also driven home the inherent difficulty in interpreting novel variants. This is particularly true for novel intronic variants beyond the ± 1~2 canonical splice sites as well as synonymous variants, which do not typically impact protein structure but may affect gene function through disruption of normal splicing. Functional studies are necessary to determine pathogenicity of these variants.
Conclusions
We identified and characterized a splice site variant, c.5332+4delA, in an individual with early-onset breast cancer that affects splicing resulting in the loss of exon 21-an isoform that is not a naturally occurring alternatively spliced BRCA1 isoform, supporting a Likely Pathogenic classification according to ACMG guidelines [32] .
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